Europe Stem Cell Therapy Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144041
- Pages: 225
-
Format:
Short Description
Europe Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (Italy, Belgium, Czech Republic, Germany, U.K., Spain, Hungary, and Poland) Industry Trends and Forecast to 2029
Market Definition:
Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.
Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.
Market Segmentation:
The Europe stem cell therapy market is categorized into product type, type, applications, end user, and distribution channel.
On the basis of product type, the Europe stem cell therapy market is segmented into placental or umbilical stem cell, bone marrow derived mesenchymal cells, adipose tissue derived mesenchymal stem cells, and others
On the basis of type, the Europe stem cell therapy market is segmented into allogenic stem cell therapy and autologous stem cell therapy
On the basis of application, the Europe stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, and others
On the basis of end user, the Europe stem cell therapy market is segmented into hospitals and surgical centers, therapeutic companies, services companies, and others
On the basis of distribution channel, the Europe stem cell therapy market is segmented into direct tenders and third party distributor
Market Players
Some of the major players operating in the Europe stem cell therapy market are:
Takeda Pharmaceutical Company Limited
Holostem Terapie Avanzate S.r.l.
JCR Pharmaceuticals Co., Ltd
ANTEROGEN.CO., LTD
MEDIPOST
Orthofix Medical Inc.
BioRestorative Therapies, Inc.
STEMPEUTICS RESEARCH PVT LTD
Pluristem Inc.
TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF THE EUROPE STEM CELL THERAPY MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 18
2 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 DBMR TRIPOD DATA VALIDATION MODEL 23
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT SEGMENT LIFELINE CURVE 27
2.8 DBMR MARKET POSITION GRID 28
2.9 VENDOR SHARE ANALYSIS 30
2.10 MARKET END USER COVERAGE GRID 31
2.11 SECONDARY SOURCES 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 37
4.1 PESTEL 38
4.2 PORTER'S FIVE FORCES MODEL 39
5 EPIDEMIOLOGY 40
6 PIPELINE ANALYSIS FOR THE EUROPE STEM CELL THERAPY MARKET 41
7 EUROPE STEM CELL THERAPY MARKET: REGULATIONS 42
8 MARKET OVERVIEW 45
8.1 DRIVERS 47
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 47
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 48
8.1.3 GROWING BIOTECHNOLOGY SECTOR 49
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 50
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 50
8.2 RESTRAINTS 51
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 51
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 51
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 52
8.2.4 AVAILABILITY OF ALTERNATIVES 52
8.3 OPPORTUNITIES 53
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 53
8.3.2 RISE IN HEALTHCARE EXPENDITURE 53
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 54
8.4 CHALLENGES 54
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 54
8.4.2 STRINGENT REGULATIONS 55
9 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE 57
9.1 OVERVIEW 58
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 61
9.3 PLACENTAL/UMBILICAL STEM CELL 61
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 62
9.5 OTHERS 63
10 EUROPE STEM CELL THERAPY MARKET, BY TYPE 65
10.1 OVERVIEW 66
10.2 ALLOGENEIC STEM CELL THERAPY 69
10.2.1 MUSCULOSKELETAL DISORDERS 70
10.2.2 WOUNDS AND INJURIES 70
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 70
10.2.4 SURGERIES 70
10.2.5 GASTROINTESTINAL DISEASES 70
10.2.6 OTHER APPLICATION 70
10.3 AUTOLOGOUS STEM CELL THERAPY 70
10.3.1 CARDIOVASCULAR DISEASES 72
10.3.2 GASTROINTESTINAL DISEASES 72
10.3.3 OTHER APPLICATION 72
11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION 73
11.1 OVERVIEW 74
11.2 MUSCULOSKELETAL DISORDERS 76
11.3 WOUNDS AND INJURIES 77
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 78
11.5 SURGERIES 79
11.6 GASTROINTESTINAL DISEASES 80
11.7 CARDIOVASCULAR DISEASES 80
11.8 OTHER APPLICATION 81
12 EUROPE STEM CELL THERAPY MARKET, BY END USER 83
12.1 OVERVIEW 84
12.2 HOSPITAL AND SURGICAL CENTERS 87
12.3 THERAPEUTIC COMPANIES 87
12.4 SERVICES COMPANIES 88
12.5 OTHERS 89
13 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 90
13.1 OVERVIEW 91
13.2 DIRECT TENDER 95
13.3 THIRD PARTY DISTRIBUTORS 95
14 EUROPE STEM CELL THERAPY MARKET, BY REGION 97
14.1 EUROPE 98
14.1.1 ITALY 104
14.1.2 BELGIUM 106
14.1.3 CZECH REPUBLIC 108
14.1.4 GERMANY 110
14.1.5 U.K. 112
14.1.6 SPAIN 114
14.1.7 HUNGARY 116
14.1.8 POLAND 118
15 EUROPE STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 120
15.1 COMPANY SHARE ANALYSIS: EUROPE 120
16 SWOT ANALYSIS 121
17 COMPANY PROFILE 122
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 122
17.1.1 COMPANY SNAPSHOT 122
17.1.2 REVENUE ANALYSIS 122
17.1.3 COMPANY SHARE ANALYSIS 123
17.1.4 PRODUCT PORTFOLIO 123
17.1.5 RECENT DEVELOPMENT 123
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 124
17.2.1 COMPANY SNAPSHOT 124
17.2.2 REVENUE ANALYSIS 124
17.2.3 COMPANY SHARE ANALYSIS 125
17.2.4 PRODUCT PORTFOLIO 125
17.2.5 RECENT DEVELOPMENTS 125
17.3 ORTHOFIX MEDICAL INC. (2021) 126
17.3.1 COMPANY SNAPSHOT 126
17.3.2 REVENUE ANALYSIS 126
17.3.3 COMPANY SHARE ANALYSIS 127
17.3.4 PRODUCT PORTFOLIO 127
17.3.5 RECENT DEVELOPMENTS 127
17.4 MEDIPOST (2021) 129
17.4.1 COMPANY SNAPSHOT 129
17.4.2 REVENUE ANALYSIS 129
17.4.3 COMPANY SHARE ANALYSIS 130
17.4.4 PRODUCT PORTFOLIO 130
17.4.5 RECENT DEVELOPMENTS 130
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 132
17.5.1 COMPANY SNAPSHOT 132
17.5.2 REVENUE ANALYSIS 132
17.5.3 COMPANY SHARE ANALYSIS 133
17.5.4 PRODUCT PORTFOLIO 133
17.5.5 RECENT DEVELOPMENT 133
17.6 CORESTEM, INC. (2021) 134
17.6.1 COMPANY SNAPSHOT 134
17.6.2 REVENUE ANALYSIS 134
17.6.3 PRODUCT PORTFOLIO 135
17.6.4 RECENT DEVELOPMENT 135
17.7 PHARMICELL CO., LTD. (2021) 136
17.7.1 COMPANY SNAPSHOT 136
17.7.2 PRODUCT PORTFOLIO 136
17.7.3 RECENT DEVELOPMENTS 136
17.8 ANTEROGEN.CO., LTD (2021) 137
17.8.1 COMPANY SNAPSHOT 137
17.8.2 PRODUCT PORTFOLIO 137
17.8.3 RECENT DEVELOPMENTS 137
17.9 ATHERSYS, INC.(2021) 138
17.9.1 COMPANY SNAPSHOT 138
17.9.2 REVENUE ANALYSIS 138
17.9.3 PRODUCT PORTFOLIO 139
17.9.4 RECENT DEVELOPMENTS 139
17.10 BRAINSTORM CELL LIMITED (2021) 140
17.10.1 COMPANY SNAPSHOT 140
17.10.2 PRODUCT PORTFOLIO 140
17.10.3 RECENT DEVELOPMENTS 140
17.11 BIORESTORATIVE THERAPIES, INC. (2021) 142
17.11.1 COMPANY SNAPSHOT 142
17.11.2 REVENUE ANALYSIS 142
17.11.3 PRODUCT PORTFOLIO 143
17.11.4 RECENT DEVELOPMENTS 143
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 144
17.12.1 COMPANY SNAPSHOT 144
17.12.2 PRODUCT PORTFOLIO 144
17.12.3 RECENT DEVELOPMENTS 144
17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 146
17.13.1 COMPANY SNAPSHOT 146
17.13.2 REVENUE ANALYSIS 146
17.13.3 PRODUCT PORTFOLIO 147
17.13.4 RECENT DEVELOPMENT 147
17.14 MESOBLAST LTD (2021) 148
17.14.1 COMPANY SNAPSHOT 148
17.14.2 REVENUE ANALYSIS 148
17.14.3 PRODUCT PORTFOLIO 149
17.14.4 RECENT DEVELOPMENTS 149
17.15 PLURISTEM INC.(2021) 150
17.15.1 COMPANY SNAPSHOT 150
17.15.2 REVENUE ANALYSIS 150
17.15.3 PRODUCT PORTFOLIO 151
17.15.4 RECENT DEVELOPMENT 151
17.16 STEMPEUTICS RESEARCH PVT LTD 152
17.16.1 COMPANY SNAPSHOT 152
17.16.2 PRODUCT PORTFOLIO 152
17.16.3 RECENT DEVELOPMENTS 152
17.17 U.S. STEM CELL, INC. (2021) 154
17.17.1 COMPANY SNAPSHOT 154
17.17.2 REVENUE ANALYSIS 154
17.17.3 PRODUCT PORTFOLIO 155
17.17.4 RECENT DEVELOPMENT 155
18 QUESTIONNAIRE 156
19 RELATED REPORTS 159
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
